[A19-100] Pembrolizumab (head and neck squamous cell carcinoma, monotherapy) - Benefit assessment according to §35a Social Code Book V
Last updated 02.03.2020
Commission awarded on 02.12.2019 by the Federal Joint Committee (G-BA).
First-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express PD-L1
Metastatic disease stage: hint of non-quantifiable, but at least considerable added benefit; recurrent disease stage: hint of considerable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.